The best-known CJC-1295 human studies tested an albumin-binding DAC construct. A product labeled “CJC-1295 without DAC” lacks that defining feature, so quoting the 5.8–8.1 day half-life for it is an evidence error.
What the record shows
- The classic CJC-1295 trials studied the DAC, albumin-binding form.
- Older GRF(1-29) studies demonstrate short-peptide endocrine activity but do not prove that every modified GRF product is identical.
- Without an exact sequence and modification record, the catalog name is analytically ambiguous.
Study record
A 1984 study gave GRF1-44, GRF1-40 and GRF1-29 to five healthy volunteers and observed GH peaks 15–30 minutes later. That study is useful background for short GHRH fragments, but it predates and does not identify a commercial “CJC-1295 without DAC” lot.
Results in context
The medicinal-chemistry literature describes multiple substitutions and terminal modifications designed to alter degradation and receptor activity. “Modified GRF 1-29” therefore needs a sequence-level definition.
A scientifically accurate page can explain the related GHRH pathway while making the direct-evidence gap visible.
Identity correction (reviewed 2026-08-28): “CJC-1295 without DAC” is a commercial naming convention, not proof of one exact sequence, counterion or terminal form. The classic DAC pharmacokinetic record cannot be transferred, and a current specification plus lot-specific analytical record is required before assigning molecular identity.
What this study cannot answer
Background GRF1-29 studies are not matched trials of the catalog material.
No long-acting DAC pharmacokinetic number should appear as a without-DAC specification.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- GRF1-29 compared with longer human GRF fragmentsLosa M, et al. Klin Wochenschr. 1984. PMID 6240568.
- Potent long-acting GRF analoguesRivier J, et al. Ann N Y Acad Sci. 1988. PMID 3133968.
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
